StreetAlpha
13F holdings · Q3 2026

NEXTBio Capital Management

Austin, TX · files as NEXTBio Capital Management LP
Know the moment NEXTBio Capital Management filesYou follow NEXTBio Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 2038158

NEXTBio Capital Management reported 25 stocks worth $234M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PTGX (13.2%), STTK (10.8%) and CMPS (9.4%). Compared with Q2 2026, the fund opened new positions in ENTX, KRSA and BLSM, added to PHVS, XENE and ZLAB, trimmed VOR, PVLA and ORIC and sold out of BIOA and ACET.

Latest filing: what NEXTBio Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
5 new5 added4 trimmed2 sold outBought about $38.2M · sold about $13.8M
New 5
Added 5
Trimmed 4
Sold out 2

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$234M+7.8% vs last quarter
Stocks held255 new · 2 sold out
Top 5 weight43.9%fairly concentrated
Turnover22%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
PTGX
Protagonist Therapeutics Inc
$30.9M13.2%219KNo change4 of 4
2
STTK
Shattuck Labs Inc
$25.4M10.8%3.7MNo change4 of 4
3
CMPS
Compass Pathways PLC
$22.1M9.4%1.8MNo change4 of 4
4
RYTM
Rhythm Pharmaceuticals Inc
$12.5M5.3%132KNo change4 of 4
5
VOR
Vor Biopharma Inc Com New
$11.8M5.0%621K−268K (−30%)4 of 4
6
PHVS
Pharvaris N V
$11.8M5.0%373K+264K (+245%)2 of 4
7
XENE
Xenon Pharmaceuticals Inc
$11.5M4.9%310K+127K (+69%)4 of 4
8
ZBIO
Zenas Biopharma Inc
$11.5M4.9%427KNo change4 of 4
9
PVLA
Palvella Therapeutics Inc NE
$11.1M4.7%80K−9,500 (−11%)4 of 4
10
GPCR
Structure Therapeutics Inc
$9.8M4.2%312KNo change4 of 4
🔒 15 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
BIOA
Bioage Labs Inc
$2.5M101K
ACET
Adicet Bio Inc
$1.4M158K

Reported value

last 4 quarters
$170MQ4 '25
$215MQ1 '26
$217MQ2 '26
$234MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

NEXTBio Capital Management 13F FAQ

What does NEXTBio Capital Management own?

NEXTBio Capital Management reported 25 stocks worth $234M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PTGX (13.2%), STTK (10.8%) and CMPS (9.4%). The table above lists every position in the filing (the top 10 without an account).

What did NEXTBio Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 5 new positions, 5 added to, 4 trimmed and 2 sold out. New positions include ENTX, KRSA and BLSM. It sold all of BIOA and ACET.

When will NEXTBio Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is NEXTBio Capital Management's portfolio worth?

The Q3 2026 filing reports $234M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.